吡非尼酮降低特发性肺纤维化呼吸相关住院风险
该分析汇总三项III期随机安慰剂对照试验的个体患者数据,比较吡非尼酮2,403 mg/d(n=623)与安慰剂(n=624)52周内非计划住院及住院后死亡风险。吡非尼酮组呼吸相关住院风险低于安慰剂组(7% vs. 12%;HR 0.52;95%CI 0.36-0.77;P=0.001),全因及非呼吸相关住院风险无显著差异。
要点
- 吡非尼酮组呼吸相关住院风险显著低于安慰剂组(7% vs. 12%;HR 0.52)。
- 全因住院(HR 0.91;P=0.528)与非呼吸相关住院(HR 1.32;P=0.145)风险无显著差异。
- 住院后死亡风险在52周内较低,但延长随访后该关联不再显著。
核心结论
- 在1年观察期内,接受吡非尼酮治疗的特发性肺纤维化患者非计划呼吸相关住院风险低于安慰剂组。
- 吡非尼酮对住院后死亡的影响尚不确定。
研究设计与样本
- 三项III期随机、安慰剂对照吡非尼酮治疗特发性肺纤维化试验(两项CAPACITY试验和一项ASCEND试验)的个体患者数据汇总分析。
- 纳入所有随机分配至吡非尼酮2,403 mg/d(n=623)或安慰剂(n=624)的患者,共1,247例(CAPACITY 692例,ASCEND 555例)。
- 采用标准时间-事件方法比较52周住院风险;对住院患者,经治疗组倾向调整后比较住院后死亡风险。
主要发现
- 吡非尼酮组呼吸相关住院风险低于安慰剂组(7% vs. 12%;HR 0.52;95%CI 0.36-0.77;P=0.001)。
- 全因住院风险两组无显著差异(HR 0.91;95%CI 0.70-1.19;P=0.528)。
- 非呼吸相关住院风险两组无显著差异(HR 1.32;95%CI 0.92-1.88;P=0.145)。
- 因任何原因住院者中,吡非尼酮治疗与随机化后52周内住院后死亡风险较低相关,但延长随访后该关联不再显著。
关键数值与推荐
- 呼吸相关住院:吡非尼酮组7% vs. 安慰剂组12%;HR 0.52;95%CI 0.36-0.77;P=0.001。
- 全因住院:HR 0.91;95%CI 0.70-1.19;P=0.528。
- 非呼吸相关住院:HR 1.32;95%CI 0.92-1.88;P=0.145。
- 吡非尼酮剂量:2,403 mg/d;观察期:52周。
临床怎么用
- 对特发性肺纤维化患者,吡非尼酮治疗可能降低1年内呼吸相关住院风险,可作为评估治疗获益的参考。
- 不应依据本分析认为吡非尼酮可降低全因住院或非呼吸相关住院风险。
- 吡非尼酮对住院后死亡的影响不确定,临床决策需结合个体情况。
局限性
- 为三项试验的汇总分析,非预设汇总分析,解读需谨慎。
- 住院后死亡分析采用倾向调整,且延长随访后关联不再显著,因果推断受限。
- 原文未报告各试验间异质性及汇总分析的具体统计方法细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent than those for acute IPF exacerbations and are associated with poor outcomes. OBJECTIVES: To compare the risk of nonelective hospitalization by type (all-cause, respiratory related, and non-respiratory related) and death after hospitalization with use of pirfenidone versus placebo over 52 weeks using data derived from three phase III IPF clinical trials. METHODS: Individual patient data was pooled from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the two CAPACITY [Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes] trials and the ASCEND [Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] trial), including all patients randomized to pirfenidone 2,403 mg/d (n = 623) or placebo (n = 624). The risk of hospitalization over 52 weeks was compared using standard time-to-event methods. Among those hospitalized, the risk of death after hospitalization was compared with adjustment for treatment group propensity. MEASUREMENTS AND MAIN RESULTS: A total of 1,247 patients (692 from the CAPACITY trials and 555 from the ASCEND trial) were included in the pooled analysis. Pirfenidone was associated with lower risk of respiratory-related hospitalization than placebo (7% vs. 12%; hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.36-0.77; P = 0.001), but all-cause (HR, 0.91; 95% CI, 0.70-1.19; P = 0.528) or non-respiratory-related hospitalization (HR, 1.32; 95% CI, 0.92-1.88; P = 0.145) was not. Among those hospitalized for any reason, treatment with pirfenidone was associated with lower risk of death after hospitalization up to 52 weeks after randomization, but this association was no longer significant with longer follow-up. CONCLUSIONS: In a pooled analysis of three phase III IPF clinical trials, patients receiving pirfenidone had a lower risk of nonelective respiratory-related hospitalization over the course of 1 year. The effect of pirfenidone on death after hospitalization is uncertain.
引用
- Ley B, Swigris J, Day BM, et al. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017. PMID: 28471697. doi:10.1164/rccm.201701-0091OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。